
Valeant’s outgoing CEO subpoenaed by US congressional committee
pharmafile | March 29, 2016 | News story | Medical Communications, Research and Development | Drug pricing, Michael Pearson, US, Valeant, committee, pearson, pharma, price hikes, senate aging committee, subpoena, subpoenaed
The US Senate Aging Committee has announced the issuing of a subpoena to the outgoing CEO of Valeant Pharmaceuticals, Michael Pearson, to testify before a hearing on what they refer to as the “sudden, aggressive price spikes of decades-old Rx drugs” on Wednesday April 27th.
Michael Pearson already announced his decision to step down as CEO of Valeant Pharmaceuticals once a suitable replacement is found.
The troubled Canadian drugmaker has been the subject of much criticism recently, with many lining up to take aim at their recent controversies. Hilary Clinton referred to them by naming and vowed to put a stop to their “predatory pricing” in a recent campaign advert. Shares plunged following the announcement of their Q4 2015 results which were accompanied by gloomy forecasts for the year ahead.
This will be the third such hearing from the congressional committee, which they describe as a “bipartisan investigation” which has “focused on pharmaceutical companies that operate more like hedge funds than traditional pharmaceutical companies.”
Martin Shkreli, the infamous ex-head of Turing Pharmaceuticals, and Howard Schiller, who filled in for Pearson during a period of illness, appeared before the committee in recent times. With the price of Valeant shares falling again with the announcement of Pearson’s subpoena, all eyes will be watching on Wednesday April 27th.
Sean Murray
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

Cell therapy partnership aims to bring liver disease treatment closer to US patients
Resolution Therapeutics has partnered with the Blood Centers of America (BCA) to support community-based delivery …






